Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
RNAi-focused company reports Q2 results
September 14th, 2005
CytRx Corp. (CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference (RNAi), reported financial results for the quarter ended June 30, 2005. "We are fully committed to the clinical development of our oral drug candidate arimoclomol as a treatment for those suffering from the debilitating and life-threatening consequences of ALS [amyotrophic lateral sclerosis], also known as Lou Gehrig's disease. We were pleased to have filed our investigational new drug application with the U.S. Food and Drug Administration (FDA) in May and we view the subsequent...
Source: Vaccine Weekly (2005-09-14)
|
